Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CARLBullishCorporate Developmentsnews

High materiality8/10

Carlsmed appoints new CFO as CMS reimbursement gears up for launches

Sep 28, 2026, 8:55 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Leadership change plus reaffirmed growth trajectory and reimbursement tailwinds reduce execution risk and may attract buyers ahead of product launches.

AI summary

What happened, with direct paths to the underlying reporting

Carlsmed announced CFO Richard Heppenstall effective immediately, succeeding Leo Greenstein who leaves the role. The company reaffirmed FY2026 revenue guidance of $74–$78 million, implying roughly 50% year-over-year growth. The move comes as CMS reimbursement for aprevo Lumbar fusion takes effect October 1 and new procedures are slated for launch.

Carlsmed names Rich Heppenstall as CFO; former CFO Leo exiting.
Reaffirms FY2026 revenue outlook of $74–$78 million (+50% midpoint).
CMS reimbursement for aprevo Lumbar fusion starts Oct 1; launches planned for new procedures.
New CFO brings ~30 years in healthcare/tech; leadership to drive execution.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.